ULTIMOVACS ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.63 NOK | +3.73% |
|
+15.84% | -92.97% |
| 11/06 | Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma | CI |
| 07/05 | Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 2.78Cr | - | - | - | - | - | |
| 5.37TCr | - | |||||
| 3.89TCr | ||||||
| 3.88TCr | ||||||
| 2.73TCr | ||||||
| 2.59TCr |
- Stock Market
- Equities
- ULTI Stock
- Charts Ultimovacs ASA
- Sector Chart
